Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer

• Type of Material: Article
• Authors: Hope S Rugo, University of California San Francisco; Adam Brufsky, University of Pittsburgh; Xianchen Liu, Pfizer Inc; Benjamin Li, Pfizer Inc; Lynn McRoy, Pfizer Inc; Connie Chen, Pfizer Inc; Rachel M Layman, The University of Texas MD Anderson Cancer Center; Massimo Cristofanilli, Weill Cornell Medicine; Mylin Torres, Emory University; Giuseppe Curigliano, IRCCS and University of Milano; Richard S Finn, University of California Los Angeles; Angela DeMichele, University of Pennsylvania
• Language: English
• Date: 2022-10-11
• Publisher: NATURE PORTFOLIO
• Publication Version: Final Published Version
• Copyright Statement: © 2022, Pfizer Inc.,
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1038/s41523-022-00479-x
• Title of Journal or Parent Work: NPJ BREAST CANCER
• Volume: 8
• Issue: 1
• Start Page: 114
• End Page: 114
• Grant/Funding Information: This study was sponsored and funded by Pfizer Inc. Editorial/medical writing support was provided by Jill Shults, PhD, of ICON (Blue Bell, PA, USA) and was funded by Pfizer Inc.
• Keywords: FULVESTRANT; Science & Technology; Oncology; TREATMENT PATTERNS; Life Sciences & Biomedicine; PROPENSITY SCORE; POSTMENOPAUSAL PATIENTS; OUTCOMES; FDA APPROVAL; COMBINATION

Abstract

Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC) treated with first-line palbociclib plus an aromatase inhibitor (AI) versus an AI alone in routine US clinical practice. In total, 2888 patients initiated treatment during February 3, 2015–March 31, 2020, with a potential ≥6-month follow-up (cutoff date, September 30, 2020). After stabilized inverse probability treatment weighting, median OS (95% CI) is significantly longer among palbociclib versus AI recipients (49.1 [45.2–57.7] versus 43.2 [37.6–48.0] months; hazard ratio, 0.76 [95% CI, 0.65–0.87]; P < 0.0001). Progression-free survival (95% CI) is 19.3 (17.5–20.7) versus 13.9 (12.5–15.2) months, respectively (hazard ratio, 0.70 [95% CI, 0.62–0.78]; P < 0.0001). These data support first-line palbociclib plus an AI treatment for HR+/HER2− MBC. (Trial number NCT05361655).